ImmunoPrecise Antibodies/$IPA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
Ticker
$IPA
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
87
Website
IPA Metrics
BasicAdvanced
$80M
-
-$0.66
0.46
-
Price and volume
Market cap
$80M
Beta
0.46
52-week high
$2.41
52-week low
$0.27
Average daily volume
2M
Financial strength
Current ratio
2.081
Quick ratio
1.717
Long term debt to equity
48.9
Total debt to equity
56.73
Interest coverage (TTM)
-1,237.60%
Profitability
EBITDA (TTM)
-6.738
Gross margin (TTM)
55.25%
Net profit margin (TTM)
-123.30%
Operating margin (TTM)
-50.47%
Effective tax rate (TTM)
11.77%
Revenue per employee (TTM)
$202,590
Management effectiveness
Return on assets (TTM)
-14.81%
Return on equity (TTM)
-101.96%
Valuation
Price to revenue (TTM)
3.274
Price to book
3.4
Price to tangible book (TTM)
5.6
Price to free cash flow (TTM)
-11.137
Free cash flow yield (TTM)
-8.98%
Free cash flow per share (TTM)
-0.156
Growth
Revenue change (TTM)
0.01%
Earnings per share change (TTM)
-11.10%
3-year revenue growth (CAGR)
8.19%
10-year revenue growth (CAGR)
30.11%
3-year earnings per share growth (CAGR)
2.19%
What the Analysts think about IPA
Analyst ratings (Buy, Hold, Sell) for ImmunoPrecise Antibodies stock.
IPA Financial Performance
Revenues and expenses
IPA Earnings Performance
Company profitability
IPA News
AllArticlesVideos
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
Business Wire·1 week ago
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
Business Wire·2 weeks ago
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunoPrecise Antibodies stock?
ImmunoPrecise Antibodies (IPA) has a market cap of $80M as of August 01, 2025.
What is the P/E ratio for ImmunoPrecise Antibodies stock?
The price to earnings (P/E) ratio for ImmunoPrecise Antibodies (IPA) stock is 0 as of August 01, 2025.
Does ImmunoPrecise Antibodies stock pay dividends?
No, ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next ImmunoPrecise Antibodies dividend payment date?
ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies (IPA) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.